Hmet Trio 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Voglibose 0.2mg, formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, mitigating postprandial hyperglycemia. The sustained-release formulation ensures a gradual release of active ingredients, promoting steady plasma concentrations and improved patient compliance. Hmet Trio 2 Tablet SR is indicated for patients inadequately controlled on diet, exercise, and monotherapy, providing a multifaceted approach to glycemic management by targeting different pathophysiological mechanisms of type 2 diabetes. It should be administered under medical supervision with appropriate lifestyle modifications, including diet and exercise. Caution is advised in patients with renal or hepatic impairment, and monitoring for hypoglycemia is essential due to the sulfonylurea component. This combination therapy offers an effective option for optimizing blood glucose control and reducing the risk of diabetes-related complications.